Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of acetylsalicylic acid (ASA), an irreversible inhibitor of cyclooxygenase-1 (COX-1). The enteric coating is designed to minimize local gastric mucosal irritation by delaying dissolution until the small intestine.
## Primary Indications
* **Cardiovascular:** Prophylaxis of myocardial infarction (MI), ischemic stroke, and transient ischemic attacks (TIA).
* **Acute Management:** Acute coronary syndromes (ACS).
* **Inflammatory/Pain:** Rheumatic fever and mild-to-moderate pain or inflammation (though EC formulations are suboptimal for rapid analgesic effects).
## Adult Dosing
* **Cardiovascular Prophylaxis:** 75 mg to 325 mg once daily. (Common standard maintenance dose is 81 mg or 100 mg daily).
* **Acute Coronary Syndrome (Initial):** 162 mg to 325 mg (non-enteric coated preferred for rapid absorption; chewable is ideal).
* **Analgesia/Antipyretic:** 325 mg to 650 mg every 4 to 6 hours. Maximum: 4,000 mg/day.
## Pediatric Dosing
* **Kawasaki Disease:** 80–100 mg/kg/day divided every 6 hours during the acute phase; reduce to 3–5 mg/kg daily as an antiplatelet agent once afebrile.
* **Rheumatic Fever:** 80–100 mg/kg/day divided every 4–6 hours.
* **Analgesia:** Not recommended for pediatric viral infections due to Reye’s syndrome risk.
## Dose Adjustments
* **Renal Impairment:** Use with caution; may decrease renal blood flow. Avoid in severe renal failure.
* **Hepatic Impairment:** Use with caution; avoid in severe hepatic failure.
* **Geriatric:** Increased risk of gastrointestinal bleeding; use the lowest effective dose.
## Contraindications
* Hypersensitivity to salicylates or NSAIDs.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
* History of asthma/nasal polyps exacerbated by NSAIDs (aspirin-exacerbated respiratory disease).
* Children or adolescents with viral infections (influenza/varicella) due to risk of Reye's syndrome.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, gastric ulceration/erosion (even with EC), occult blood loss.
* **Hematologic:** Increased bleeding risk (thrombocytopenia, impaired platelet aggregation).
* **Other:** Tinnitus (a sign of salicylate toxicity), bronchospasm, urticaria.
## Key Drug Interactions
* **Anticoagulants/Antiplatelets (e.g., Warfarin, DOACs, Clopidogrel):** Synergistic bleeding risk.
* **NSAIDs (e.g., Ibuprofen):** Ibuprofen may interfere with the antiplatelet effect of aspirin. If co-administered, dose aspirin 30 minutes before or 8 hours after ibuprofen.
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** Increased risk of GI bleeding.
## Monitoring
* **Baseline:** CBC (hemoglobin/hematocrit), occult blood in stool.
* **Clinical:** Signs of bleeding (bruising, dark stools, epistaxis, hematemesis).
* **Toxicity:** Monitor for tinnitus, metabolic acidosis, or hyperventilation if high-dose therapy is used.
## Clinical Pearls
* **Enteric Coating:** While it reduces gastric irritation, it does not reliably eliminate the risk of gastric ulcers.
* **Absorption:** EC aspirin is not suitable for acute cardiac events where rapid onset is required; use non-enteric, chewable, or plain aspirin for acute ACS.
* **Adherence:** Abrupt discontinuation of low-dose aspirin after a cardiac event may increase the risk of recurrent ischemic events (rebound effect).
***
**Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Dosing may vary based on local protocols and specific patient comorbidities. Always verify current prescribing information, institutional guidelines, and drug monographs before administering medications.
